Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2023 Lymphoma & CLL Highlights
27 June 2023 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in CLL & Lymphoma from ASCO, EHA & ICML 2023
The Post-ASCO & EHA 2023 CLL & Lymphoma Highlights was supported by AbbVie, AstraZeneca, Bristol Myers Squibb, Genentech and Genmab. Supporters have no influence over the production of content.
Lymphoma Part 1
ROSEWOOD: Zanubrutinib plus obinutuzumab vs obinutuzumab for FL
Christopher Flowers MD Anderson Cancer Center, Houston, TX, United States
TRANSFORM: liso-cel vs SOC as 2L therapy for LBCL
Loretta Nastoupil The University of Texas MD Anderson Cancer Center, Houston, TX, United States
ZUMA-27: axi-cel vs SOC for DLBCL
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel discussion
Lymphoma Part 2
VR-CHOP for patients with Richter Syndrome
Matthew Davids Dana-Farber Cancer Institute, Boston, MA, United States
AUTO4 for TRBC1- Positive Peripheral T-cell Lymphoma
Kate Cwynarski University College Hospital, London, United Kingdom
EPCORE NHL-1: Epcoritamab for LBCL
Anna Sureda Catalan Institute of Oncology, Barcelona, Spain
Glofitamab + Pola-R-CHP for DLBCL
Michael Dickinson Peter MacCallum Cancer Centre, Melbourne, Australia
Panel discussion
CLL Part 1
Acalabrutinib vs zanubrutinib for R/R CLL
Adam Kittai The Tisch Cancer Institute (TCI) at Mount Sinai, New York City, NY, United States
CLL12: Ibrutinib for asymptomatic, treatment-naïve early stage CLL
Barbara Eichhorst University Hospital Cologne, Cologne , Germany
BRUIN: pirtobrutinib for pretreated CLL
Jennifer Brown Dana-Farber Cancer Institute, Boston, MA, United States
Panel discussion
CLL Part 2
BRUIN CLL-322: pirtobrutinib & VEN vs rituximab + VEN for CLL
Toby Eyre Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
MOLTO: venetoclax, atezolizumab + obinutuzumab in Richter’s syndrome
Anna Maria Frustaci ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Glofitamab for Richter’s transformation
Carmelo Carlo-Stella University of Rome Tor Vergeta, Rome, Italy
TRANSCEND CLL 004: liso-cel for SLL
Tanya Siddiqi City of Hope, Duarte, CA, United States
Panel discussion
The Post-ASCO, EHA & ICML 2023 Lymphoma & CLL Highlights webinar has been supported by:
